1: Fahlenkamp UL, Adams LC, Böker SM, Engel G, Huynh Anh M, Wagner M, Hamm B, Makowski MR. Feasibility of gadoxetate disodium enhanced 3D T1 MR cholangiography (MRC) with a specific inversion recovery prepulse for the assessment of the hepatobiliary system. PLoS One. 2018 Sep 5;13(9):e0203476. doi: 10.1371/journal.pone.0203476. eCollection 2018. 2: Grazioli L, Faletti R, Frittoli B, Battisti G, Ambrosini R, Romanini L, Gatti M, Fonio P. Evaluation of incidence of acute transient dyspnea and related artifacts after administration of gadoxetate disodium: a prospective observational study. Radiol Med. 2018 Aug 6. doi: 10.1007/s11547-018-0927-y. [Epub ahead of print] doi: 10.2214/AJR.18.19786. doi: 10.2214/AJR.18.19722. doi: 10.1371/journal.pone.0200887. eCollection 2018. 7: Chen MD, Zhang J, Yang GX, Lin JM, Feng YQ. [Differential diagnosis of hepatocellular carcinoma and hepatic hemangiomas based on radiomic features of gadoxetate disodium-enhanced magnetic resonance imaging]. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Apr 20;38(4):428-433. Chinese.
合成参考文献
摘要:NIH; DailyMed. Current Medication Information for Eovist (gadoxetate disodium, injection solution) (Updated: February 2013). Available from, as of March 17, 2015: 摘要:O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 769 摘要: